# A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Study · id `cardio:ct-nct02794792` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02794792](<https://clinicaltrials.gov/study/NCT02794792>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02794792

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 268 participants.

## Technical summary

Registry record NCT02794792. Randomized; triple masking; primary purpose treatment. Start 2016-05-11 (actual); primary completion 2017-03-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 268 participants (enrolled count; ClinicalTrials.gov record NCT02794792, source copy `cardio:ctgov-nct02794792-2024-11-12`, retrieved 2026-10-26)
- Started: 2016-05-11 (actual) (ClinicalTrials.gov record NCT02794792, source copy `cardio:ctgov-nct02794792-2024-11-12`, retrieved 2026-10-26)
- Primary completion: 2017-03-02 (actual) (ClinicalTrials.gov record NCT02794792, source copy `cardio:ctgov-nct02794792-2024-11-12`, retrieved 2026-10-26)
- Completion: 2017-06-20 (actual) (ClinicalTrials.gov record NCT02794792, source copy `cardio:ctgov-nct02794792-2024-11-12`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT02794792, source copy `cardio:ctgov-nct02794792-2024-11-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02794792-2024-11-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
- Acronym: IMPRESSION
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ipragliflozin L-proline
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: Astellas Pharma Europe B.V.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Europe B.V. (`cardio:org-astellas-pharma-europe-b-v`)

## Provenance

Content hash: 7b33123a085e8ff092bec354b2739a94f17cac7ce5b51a0150fb42bbdda394bd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
